Feature | March 24, 2014

New Treatment for Atrial Fibrillation Reduces Stroke Risk

Lariat device seals the left atrial appendage

atrial fibrillation, LARIAT
March 24, 2014 – Doctors at the Stony Brook Heart Institute Electrophysiology Lab are using a new nonsurgical technique called the Lariat Suture Delivery Device to treat patients with atrial fibrillation (AF) who cannot tolerate blood-thinning medication.
 
AF is the most common heart rhythm disorder that causes the upper chambers of the heart to beat fast and erratically. An estimated 2.7 million Americans are living with the disorder, and if uncontrolled, it can have serious consequences, including stroke and early death. Currently, the condition accounts for more than 20 percent of stroke-related deaths.
 
Patients are normally given blood thinners such as warfarin and other anticoagulants to manage their condition by preventing blood clots. However, patients must rigorously manage the level of the drugs in their blood. For most patients, these blood thinners are very effective in reducing the risk of stroke, but there is a potential for bleeding, which in some cases can be serious. For those individuals who cannot tolerate blood thinners due to prior bleeding or who are at a high risk for bleeding, the Lariat procedure can safely reduce the risk of stroke without any further bleeding risk.
 
The Lariat procedure is a nonsurgical, minimally-invasive technique that uses sutures to tie off the left atrial appendage (LAA) of the heart. This area of the heart is the primary source of blood clots leading to stroke in patients with atrial fibrillation.
 
With the patient under general anesthesia, physicians guide two catheters into the patient’s heart to seal the LAA with a pre-tied suture loop — similar to a lasso — with the Lariat device. Rather than a surgical procedure, the technique uses a needle to introduce catheters into the heart.
 
“In the past there weren’t any alternatives that we could really offer these types of patients,” said Roger Fan, M.D., associate professor, department of medicine, director of arrhythmia consult service. “The Lariat is a great alternative to the possibility of a lifetime of blood thinners, which can have some serious side effects like GI bleeds, as well as an alternative to invasive open-heart surgery.” 
 
On Dec. 3, 2013, Fan and his team at the Stony Brook Heart Institute completed their first Lariat procedure without having to spread the ribcage or cut through bone to reach the heart.
 
For more information, visit www.heart.stonybrookmedicine.edu

Related Content

AtriCure, AtriClip PRO2 LAA Exclusion System, left atrial appendage, FDA clearance
Technology | Left Atrial Appendage (LAA) Occluders| April 29, 2016
April 29, 2016 — AtriCure Inc. announced U.S.
post-operative atrial fibrillation, AFib, heart rate, rhythm control, ACC.16
News | Atrial Fibrillation| April 20, 2016
In the first large randomized trial to directly compare two approaches to preventing atrial fibrillation following...
Sponsored Content | Videos | Left Atrial Appendage (LAA) Occluders| April 15, 2016
David Holmes, M.D., professor of medicine, Mayo Clinic College of Medicine and consultant, Department of Internal Med
Xarelto, rivaroxaban, PMSS study, ACC 2016, NVAF, atrial fibrillation, stroke
News | Antiplatelet and Anticoagulation Therapies| April 08, 2016
New data from an ongoing post-marketing study confirm the safety profile of Xarelto (rivaroxaban) was generally...
Kardia Band, Alivecor

The Alivecor Kardia Band for the Apple Watch enables anyone to perform a medical-grade ECG anywhere.

Technology | Wearable Sensors| March 28, 2016
AliveCor, Inc., the leader in FDA-cleared electrocardiogram (ECG) technology for mobile devices, announced today the
atrial fibrillation patients, high stroke risk, not prescribed medication, JAMA Cardiology study
News | Pharmaceuticals| March 17, 2016
Nearly half of all atrial fibrillation (AF) patients at the highest risk for stroke are not being prescribed blood...
aMAZE Trial enrollment, The Valley Hospital NJ, atrial fibrillation
News | Left Atrial Appendage (LAA) Occluders| March 16, 2016
The Valley Hospital in Ridgewood, N.J., is one of 15 U.S. sites currently enrolling patients in a research study...
Biotronik, BioMonitor 2, AF remote monitoring, atrial fibrillation, U.K. and Ireland
News | Remote Monitoring| March 14, 2016
Biotronik announced that its BioMonitor 2 heart monitor is now available for patients in the United Kingdom. The...
Boston Scientific, FDA approval, Blazer OI catheter, open irrigated
Technology | Ablation Systems| March 11, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for the Blazer Open-Irrigated (OI)...
AtriCure, AtriClip, ATLAS study, first patient enrolled, POAF, post-operative atrial fibrillation
News | Structural Heart| February 18, 2016
AtriCure Inc. announced that the first patient was enrolled and treated at PinnacleHealth Hospitals in Harrisburg, Pa...
Overlay Init